Elizabeth M. Jaffee

Johns Hopkins University, Baltimore, MD 
Cell Biology, Molecular Biology
"Elizabeth Jaffee"
BETA: Related publications


You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Yarchoan M, Mohan AA, Dennison L, et al. (2019) MEK inhibition suppresses B regulatory cells and augments anti-tumor immunity. Plos One. 14: e0224600
Elyada E, Bolisetty M, Laise P, et al. (2019) Cross-species single-cell analysis of pancreatic ductal adenocarcinoma reveals antigen-presenting cancer-associated fibroblasts. Cancer Discovery
Blair AB, Kim V, Muth S, et al. (2019) Dissecting the stromal signaling and regulation of myeloid cells and memory effector T cells in pancreatic cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research
Kim VM, Blair AB, Lauer P, et al. (2019) Anti-pancreatic tumor efficacy of a Listeria-based, Annexin A2-targeting immunotherapy in combination with anti-PD-1 antibodies. Journal For Immunotherapy of Cancer. 7: 132
Ma HS, Poudel B, Roussos Torres ET, et al. (2019) A CD40 agonist and PD-1 antagonist antibody reprogram the microenvironment of non-immunogenic tumors to allow T cell-mediated anticancer activity. Cancer Immunology Research
Christmas BJ, Rafie CI, Hopkins AC, et al. (2018) Entinostat converts immune-resistant breast and pancreatic cancers into checkpoint-responsive tumors by reprogramming tumor-infiltrating MDSCs. Cancer Immunology Research
Kinkead HL, Hopkins A, Lutz E, et al. (2018) Combining STING-based neoantigen-targeted vaccine with checkpoint modulators enhances antitumor immunity in murine pancreatic cancer. Jci Insight. 3
Emens LA, Bruno R, Rubin EH, et al. (2017) Report on the Third FDA-AACR Oncology Dose-Finding Workshop. Cancer Immunology Research. 5: 1058-1061
Foote JB, Kok M, Leatherman JM, et al. (2017) A STING Agonist Given with OX40 Receptor and PD-L1 Modulators Primes Immunity and Reduces Tumor Growth in Tolerized Mice. Cancer Immunology Research
Ladle BH, Li KP, Phillips MJ, et al. (2016) De novo DNA methylation by DNA methyltransferase 3a controls early effector CD8+ T-cell fate decisions following activation. Proceedings of the National Academy of Sciences of the United States of America
See more...